Middleton & Co. Inc. MA Sells 200 Shares of Edwards Lifesciences Co. (NYSE:EW)

Middleton & Co. Inc. MA trimmed its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 5.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,588 shares of the medical research company’s stock after selling 200 shares during the quarter. Middleton & Co. Inc. MA’s holdings in Edwards Lifesciences were worth $331,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of EW. Crewe Advisors LLC bought a new position in Edwards Lifesciences in the first quarter valued at about $28,000. First Community Trust NA bought a new position in shares of Edwards Lifesciences in the 2nd quarter worth approximately $29,000. Riverview Trust Co purchased a new position in shares of Edwards Lifesciences in the first quarter worth approximately $34,000. DSM Capital Partners LLC bought a new stake in Edwards Lifesciences during the fourth quarter valued at approximately $28,000. Finally, Webster Bank N. A. bought a new stake in Edwards Lifesciences during the second quarter valued at approximately $39,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $67.53 on Thursday. The firm has a market capitalization of $40.69 billion, a PE ratio of 29.11, a price-to-earnings-growth ratio of 2.85 and a beta of 1.13. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The firm has a 50-day moving average price of $70.89 and a 200-day moving average price of $83.11. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The business had revenue of $1.63 billion during the quarter, compared to analyst estimates of $1.65 billion. During the same quarter in the previous year, the business earned $0.66 earnings per share. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. As a group, equities research analysts forecast that Edwards Lifesciences Co. will post 2.7 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on EW shares. Baird R W downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 25th. Wolfe Research raised Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a report on Monday, July 29th. Stifel Nicolaus reduced their price target on Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating for the company in a research report on Thursday, July 25th. Daiwa Capital Markets raised Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research report on Wednesday, July 31st. Finally, StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Thursday, July 25th. Sixteen research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $79.82.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,101,530.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the transaction, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,101,530.88. The disclosure for this sale can be found here. Insiders have sold 16,250 shares of company stock valued at $1,218,138 in the last quarter. 1.29% of the stock is owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.